

# Tuberculosis profile: Pakistan

Population 2019: 217 million

## Estimates of TB burden\*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	570 000 (404 000-764 000)	263 (187-353)
HIV-positive TB incidence	5 100 (3 400-7 200)	2.4 (1.6-3.3)
MDR/RR-TB incidence**	25 000 (16 000-36 000)	12 (7.3-17)
HIV-negative TB mortality	42 000 (34 000-51 000)	19 (16-24)
HIV-positive TB mortality	1 900 (1 300-2 800)	0.9 (0.58-1.3)

## Estimated proportion of TB cases with MDR/RR-TB\*, 2019

New cases	4.2% (3.2-5.3)
Previously treated cases	7.3% (6.8-7.8)

## Universal health coverage and social protection\*


TB treatment coverage (notified/estimated incidence), 2019	58% (43-81)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	8% (5-11)

## TB case notifications, 2019

Total new and relapse	328 312
- % tested with rapid diagnostics at time of diagnosis	42%
- % with known HIV status	40%
- % pulmonary	81%
- % bacteriologically confirmed ^	50%
- % children aged 0-14 years	14%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



## HIV-negative TB mortality

(Rate per 100 000 population per year)



## Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	41%
- % men	45%
Total cases notified	334 754

### TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	624	0.48%
- on antiretroviral therapy	494	79%


### Drug-resistant TB care, 2019

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	59%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	89%
Laboratory-confirmed cases - MDR/RR-TB ^^	3 820
Patients started on treatment - MDR/RR-TB ^^^	3 004
Laboratory-confirmed cases - XDR-TB ^^	60
Patients started on treatment - XDR-TB ^^^	34
MDR/RR-TB cases tested for resistance to any fluoroquinolone	2 512


### Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2018	93%	357 893
Previously treated cases, excluding relapse, registered in 2018	82%	9 263
HIV-positive TB cases registered in 2018	51%	307
MDR/RR-TB cases started on second-line treatment in 2017	64%	2 813
XDR-TB cases started on second-line treatment in 2017	44%	77


### TB preventive treatment, 2019



### Treatment success rate



### Total budget



---

% of HIV-positive people (newly enrolled in care) on preventive treatment

---

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	5.6% (5.1-6.2)
---	-------------------

---

## TB financing

---

National TB budget, 2020 (US\$ millions)	158
--	-----

---

- Funding source, domestic	2.2%
----------------------------	------

---

- Funding source, international	32%
---------------------------------	-----

---

- unfunded	66%
------------	-----

---

\* *Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*

\*\* *MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin*

^ *Calculated for pulmonary cases only*

^^ *Includes cases with unknown previous TB treatment history*

^^^ *Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed*

---

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)